A study released Friday by UC-Hastings professor Robin Feldman and Harvard Fellow Dr. Nicholson Price predicted that biopharmaceutical companies will become a growing target of patent monetizers.
Their paper, Patent Trolling: Why Bio & Pharmaceuticals Are at Risk, examined life sciences patents—ranging from methods of treatment to active drug ingredients and dosage forms—of five research universities to evaluate their potential for assertion, using practices already observed in the technology industry. The authors characterized their search as “nonintensive,” but said they found numerous examples of patents held by universities that could be used as the basis of infringement claims against existing biotechnology and pharmaceutical products, and suggested a more intensive search by a motivated party could dig up plenty more. In particular, they looked at patents covering active ingredients, methods of treatment, manufacturing methods, dosage forms and screening methods. They also spelled out specific patents within each category.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
